Search the Newsreel

RBC Adjusts Price Target on CorMedix to $14 From $13, Maintains Outperform Speculative Risk Rating

RBC Capital Markets has increased its price target for CorMedix (CRMD) to $14 from $13, while reiterating an Outperform Speculative Risk rating. This adjustment reflects a positive outlook on the company's financial prospects and potential market performance.

CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains

CorMedix Therapeutics (CRMD) reported strong Q2 2026 results, with adjusted earnings and consolidated revenues surpassing analyst estimates, primarily driven by strong DefenCath sales and the contribution from the acquired Melinta portfolio. Following these positive results, management raised its full-year EBITDA outlook. The stock saw …

CRMD News | CORMEDIX INC (NASDAQ:CRMD)

CorMedix Inc (NASDAQ:CRMD) Receives Average Rating of "Moderate Buy" from Brokerages

CorMedix Inc (NASDAQ:CRMD) has received an average "Moderate Buy" rating from brokerages, with six out of eight analysts recommending a buy and two recommending a hold. The company's average 12-month price target is $14.86. This follows a strong second quarter where CorMedix beat revenue …

CorMedix Inc. Q2 2026 Earnings Call Summary

CorMedix Inc. Q2 2026 Earnings Call Summary - Moby Strategic Execution and Commercial Expansion Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. …

Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

CorMedix Therapeutics reported strong second-quarter 2026 financial results with $101.9 million in consolidated revenue and $26.0 million in net income, driven by robust sales of DefenCath and contributions from the acquired Melinta portfolio. The company maintained its full-year 2026 revenue guidance and raised its …

CorMedix Q2 Earnings Call Highlights

High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 CorMedix (NASDAQ:CRMD) reported second-quarter 2026 consolidated revenue of $101.9 million and adjusted EBITDA of $58.7 million, while reaffirming its full-year revenue outlook and raising adjusted EBITDA guidance. The company also said it signed …

CorMedix CEO Expects Supplemental Filing For Fungal Disease Treatment By Q3 – CRMD Stock Sees Best Day In Nearly 10 Months After Earnings Beat

CorMedix Stock Jumps on Strong DefenCath Sales

CorMedix (NASDAQ:CRMD) Shares Gap Up Following Earnings Beat

CorMedix (NASDAQ:CRMD) shares gapped up after reporting strong quarterly earnings, with EPS of $0.29 beating expectations of $0.24 and revenue of $101.93 million exceeding the $96.04 million consensus. The stock opened at $8.39, up from its previous close of $7.10, and traded around $8.76. …

CorMedix (CRMD) Q2 Earnings and Revenues Top Estimates

CorMedix Inc. (CRMD) revenue jumps as Melinta deal boosts Q2 2026 profit

CorMedix reports Q2 2026 consolidated revenue $101.9M, net income $26.0M, adjusted EBITDA $58.7M

CorMedix reported strong Q2 2026 financial results with consolidated revenue of $101.9 million, net income of $25.99 million, and adjusted EBITDA of $58.7 million. The company maintained its full-year 2026 revenue guidance and raised its adjusted EBITDA outlook, driven by significant DefenCath sales momentum …

Form 8K CorMedix Inc For: 13 August By Investing.com

This article announces that CorMedix Inc. filed a Form 8K on August 13th, as reported by Investing.com. The brief piece serves as a notification of the SEC filing and provides a direct link to view all comments related to this news.

CorMedix (CRMD) Earnings Date and Reports 2026

CorMedix Inc $CRMD Shares Purchased by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. significantly increased its stake in CorMedix Inc. (NASDAQ:CRMD) by 150.6% in the second quarter, now holding 438,629 shares valued at approximately $3.44 million. This increased institutional interest comes as CorMedix reported strong quarterly results, beating EPS and revenue …

CorMedix receives preliminary court approval for derivative lawsuit settlement

CorMedix Inc. announced that a U.S. District Court has granted preliminary approval for the settlement of a consolidated shareholder derivative lawsuit. A final settlement hearing is scheduled for September 23, 2026. The company also recently reported strong Q1 2026 earnings and upheld a patent …

Earnings Preview: CorMedix to Report Financial Results Pre-market on August 13

This article announces that CorMedix (CRMD) is scheduled to report its financial results pre-market on August 13. Investors will be keen to see if the company met expectations, with analysts forecasting a loss of $0.06 per share and revenues of $0.46 million. The report …

Form 8K CorMedix Inc For: 7 August By Investing.com

This article reports on CorMedix Inc.'s (CRMD) filing of a Form 8K on August 7. The filing is a standard SEC document used by companies to announce unscheduled material events or corporate changes that shareholders should know about. The brief piece indicates that Investing.com …

CorMedix secures preliminary court approval for derivative settlement, to adopt governance reforms

CorMedix has received preliminary court approval for a proposed derivative settlement which includes the implementation of corporate governance reforms for at least 3.5 years. A final hearing is scheduled for September 23, 2026. The settlement does not provide a monetary fund for stockholders, and …

Pacer Advisors Inc. Purchases 326,724 Shares of CorMedix Inc $CRMD

Pacer Advisors Inc. significantly increased its stake in CorMedix Inc. by 128.7% in the first quarter, acquiring an additional 326,724 shares to hold a total of 580,620 shares valued at $3.94 million. Institutional investors now collectively own 34.18% of CRMD, while analysts maintain a …

Empowered Funds LLC Grows Position in CorMedix Inc $CRMD

Empowered Funds LLC significantly increased its stake in CorMedix Inc (NASDAQ:CRMD) by 102.1% in the first quarter, now owning 266,637 shares valued at $1.81 million. Institutional investors collectively hold 34.18% of Cor

(CRMD) Risk Channels and Responsive Allocation

This article from Stock Traders Daily analyzes Cormedix Inc. (NASDAQ: CRMD), highlighting strong near-term sentiment that could challenge persistent mid and long-term weakness. It identifies an exceptional 89.0:1 risk-reward setup, targeting a 27.1% gain versus a 0.3% risk. The analysis includes three AI-generated trading …

CorMedix Inc (CRMD) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of CorMedix Inc (CRMD), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. As of July 31, 2026, CRMD's price momentum score is 4.15, and the stock is trading between a …

CorMedix (CRMD) Projected to Announce Quarterly Earnings on Thursday

CorMedix (NASDAQ: CRMD) is projected to announce its Q2 2026 earnings before market open on Thursday, August 6th, with analysts expecting $0.26 EPS and $96.04 million in revenue. The company's previous quarter saw it beat estimates with $0.43 EPS and $127.43 million in revenue, …

CorMedix schedules Aug. 13 update before markets open

CorMedix Therapeutics (Nasdaq: CRMD) announced it will release its second-quarter 2026 financial results before the market opens on Thursday, August 13, 2026. The company will also host a corporate update conference call at 8:30 a.m. Eastern Time on the same day. Investors can access …

CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026

CorMedix Therapeutics (Nasdaq: CRMD) announced it will release its second-quarter 2026 financial results before the market opens on Thursday, August 13, 2026. Following the release, the company will host a corporate update conference call at 8:30 a.m. Eastern Time. CorMedix is a biopharmaceutical company …

CorMedix Inc. Revenue Breakdown – MUN:19KA

CorMedix Inc. (19KA on the Munich Stock Exchange) generated €265.39 million in revenue last year. The Drug segment was the top performer, contributing €259.12 million, a significant increase from €41.99 million the previous year. The United States was the largest geographical contributor, matching the …

CorMedix Inc (CRMD) Valuation: PE, PB & Fair Value Analysis

CorMedix Inc (CRMD) currently holds a valuation score of 8.22, placing it at 100 out of 155 in the Pharmaceuticals industry. The company's P/E ratio stands at 3.12, significantly below its recent high and above its recent low. Key valuation metrics like P/B, P/S, …

CorMedix Inc (CRMD) Income Statement

This article provides a detailed income statement for CorMedix Inc (CRMD), offering quarterly and annual financial performance data. It covers key metrics such as total revenue, cost of revenue, operating expenses, and net income, alongside year-over-year percentage changes. The data is presented in a …

CorMedix Inc (CRMD) Cash Flow

This article provides a detailed cash flow statement for CorMedix Inc (CRMD), covering quarterly and annual data for operating, investing, and financing activities. It also includes key financial metrics like market cap, P/E ratio, and explanations of different cash flow types and their significance …

ETFs Investing in CorMedix Inc. Stocks

This article lists various ETFs that hold CorMedix Inc. (A2PF3G) stocks, providing investors with options to gain exposure to the company. The ETFs range across different investment styles and focus areas, including small-cap, health care, and biotechnology, offering diversified investment opportunities. Each listed ETF …

CRMD|CorMedix Inc|Price:7.870|Chg%:-0.180

This article provides a comprehensive financial overview of CorMedix Inc. (CRMD), including its stock performance, market capitalization, and key financial indicators from its income statement, balance sheet, and cash flow statement. It highlights the company's latest earnings, revenue, EPS, and analyst ratings, alongside detailed …